What is new in uremic toxicity? by Vanholder, Raymond et al.
REVIEW
What is new in uremic toxicity?
Raymond Vanholder & Steven Van Laecke &
Griet Glorieux
Received: 29 October 2007 /Revised: 13 December 2007 /Accepted: 28 December 2007 / Published online: 7 March 2008
# IPNA 2008
Abstract Uremic syndrome results from a malfunctioning
of various organ systems due to the retention of compounds
which, under normal conditions, would be excreted into the
urine and/or metabolized by the kidneys. If these com-
pounds are biologically active, they are called uremic
toxins. One of the more important toxic effects of such
compounds is cardio-vascular damage. A convenient
classification based on the physico-chemical characteristics
affecting the removal of such compounds by dialysis is: (1)
small water-soluble compounds; (2) protein-bound com-
pounds; (3) the larger “middle molecules”. Recent develop-
ments include the identification of several newly detected
compounds linked to toxicity or the identification of as yet
unidentified toxic effects of known compounds: the
dinucleotide polyphosphates, structural variants of angio-
tensin II, interleukin-18, p-cresylsulfate and the guanidines.
Toxic effects seem to be typically exerted by molecules
which are “difficult to remove by dialysis”. Therefore,
dialysis strategies have been adapted by applying mem-
branes with larger pore size (high-flux membranes) and/or
convection (on-line hemodiafiltration). The results of recent
studies suggest that these strategies have better outcomes,
thereby clinically corroborating the importance attributed in
bench studies to these “difficult to remove” molecules.
Keywords Convection.High-fluxdialysis.Middle
molecules.Protein-boundmolecules.Removalbydialysis.
Uremia.Uremictoxins
Introduction
A vast proportion of the patients with chronic kidney
disease (CKD) suffer from a progressive loss of glomerular
filtration, whereby the kidneys lose their capacity to remove
potentially toxic compounds from the blood stream into the
urine, resulting in their accumulation in the body [1, 2]. As
a result of this accumulation, these compounds are called
uremic retention solutes, and if they are biologically/
biochemically active, they are called uremic toxins. The
accumulation of such compounds has a negative impact on
many body functions (Table 1) and results in a gradual,
endogenous intoxication. Retention solutes, despite being
non-toxic, can still be of interest, as useful markers for
other yet toxic elements.
Among the toxic effects, cardio-vascular damage is a
major point of concern because it is responsible for
substantial morbidity and mortality, even at the early stages
of CKD [3, 4]. Of note, many of the toxic organic effects of
uremia (e.g. anemia, inflammation; Table 1) also impact on
the cardio-vascular status.
The consideration to classify uremic molecules is
inspired by a need to simplify and structure the complex
picture of uremic retention, especially within the framework
of pursuing more rational, organized and adequate thera-
peutic approaches. The classification system which is most
currently applied at present (see below) is inspired by the
behavior of uremic retention solutes during dialysis therapy.
It can be assumed that, if new therapeutic and preventive
strategies emerge in the future, other classification systems
may become appropriate as well. These might be inspired
by alternative removal strategies, such as adsorption or
convection, by pharmacologic therapies restoring pathways
activated or blocked by uremic toxins or by pathophysio-
logical mechanisms per se.
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The classification system which currently is most often
applied is essentially based on the physico-chemical
characteristics of the molecules that influence solute
removal by dialysis or related strategies (Table 2)[ 5].
Three major groups can be identified:
1) Small water-soluble compounds, whose molecular
weight (MW) is arbitrarily defined as 500 Da maxi-
mally. The prototypes are urea and creatinine, which
are easily removed by any dialysis strategy. Com-
pounds in this group do not necessarily have a marked
toxic activity.
2) The middle molecules, whose MW is arbitrarily set at
being more than 500 Da. The prototype is β2-micro-
globulin. These molecules can only be removed by
dialysis strategies which employ dialyzer membranes
containing pores large enough to allow these molecules
to cross the membrane (either peritoneal dialysis or
high-flux hemodialysis strategies). Shifting the dialysis
approach from diffusion, whereby solutes are moved
passively from one compartment to another (mostly but
not exclusively from plasma water to dialysate) to
convection, whereby solutes are actively dragged out of
the plasma by imposing water shifts through the
membrane, thereby inducing substantial amounts of
ultrafiltration (hemofiltration–hemodiafiltration), usual-
ly facilitates their removal [6]. Many of the compounds
in this group are peptides that affect a host of organ
systems.
Some of the larger middle molecules have a MW of
more than 15,000 Da, and they are sometimes called
low-MW proteins, although all peptides, even those
much smaller than 15,000 Da, semantically and
chemically comply with this qualification as low-MW
proteins.
3) The protein-bound compounds. Most of the solutes in
this group have a low MW, but some have middle-
molecule characteristics (e.g. leptin, the cytokines).
Prototypes are the phenols and indoles. These com-
pounds are difficult to remove by most of the currently
available dialysis strategies, including high-flux dialy-
sis [7]; many of the compounds in this group have
toxic activity.
In 2003, the European Uremic Toxin Work Group
(EUTox) took the initiative to generate an encyclopedic
overview of the uremic retention solutes which were known
at that moment, and identified 90 different compounds
which were subsequently classified as described above
(Table 3)[ 5]. Since this initiative, several other compounds
have been identified, and at least 25 additional solutes have
been recognized (Table 3).
Clinical implications
Uremic toxicity affects almost every organ system; there-
fore, we consider it beyond the scope of this publication to
review every toxic effect of each individual compound on
Table 2 Current classification of uremic retention solutes
Classification Characteristics Prototypes Toxicity
Small water-soluble molecules MW < 500 Da, easily removed by any
dialysis strategy
Urea, creatinine Not necessarily toxic
Middle molecules MW > 500 Da, removed only through
large-pored membranes
β2-M, leptin Large array of biological impacts
Protein-bound molecules Any MW, difficult to remove with any
dialysis strategy
Phenols, indoles Large array of biological impacts
MW Molecular weight, β2-M β2-microglobulin
Organic toxic effects of CKD
-Anemia
a
-Immune dysfunction
a
-Osteodystrophy
a
-Hyperparathyroidism
a
-Insulin resistance
a
-Malnutrition
a
-Inflammation
a
-Coagulatory disorders
a
-Skin atrophy
-Pruritus
-Polyneuritis
-Coordination disturbances
-Tremor
-Cardiac failure
a
-Loss of strength
-Anorexia
-Pericarditis
a
-Hypertension
a
-Fluid overload
a
-Cardio-vascular disease
b
Table 1 Organic toxic effects
of chronic kidney disease
(CKD)
aConditions that conceivably
have an indirect or direct impact
on cardio-vascular status
bCardio-vascular disease is con-
sidered to be the main condition
affectingoutcomeofCKDpatients
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Small water-soluble compounds Protein-bound compounds Middle molecules
Listed in the 2003 review by EUTox [5]
1-Methyladenosine 2-Methoxyresorcinol Adrenomedullin
1-Methylguanosine 3-Deoxyglucosone Atrial natriuretic peptide
1-Methylinosine CMPF β2-Microglobulin
ADMA Fructoselysine β-Endorphin
α-keto-δ-Guanidinovaleriate Glyoxal β-Lipotropin
α-N-Acetylarginine Hippuric acid Cholecystokinin
Arabinitol Homocysteine Clara cell protein
Argininic acid Hydroquinone Complement factor D
Benzylalcohol Indole-3-acetate Cystatin C
β-Guanidinopropionate Indoxyl sulfate DIP I
Creatine Kinurenine δ-Sleep-inducing peptide
Creatinine Kinurenic acid Endothelin
Cytidine Melatonin Hyaluronic acid
Dimethylglycine Methylglyoxal Interleukin-1β
b
Erythritol N
ɛ-Carboxymethyllysine Interleukin-6
b
γ-Guanidinobutyrate p-Cresol
a κ-Ig Light chain
Guanidine Pentosidine λ-Ig Light chain
Guanidinoacetate Phenol Leptin
b
Guanidinosuccinate p-OHhippurate Methionine-enkephalin
Hypoxanthine Putrescine Neuropeptide Y
Malondialdehyde Quinolinic acid Parathyroid hormone
Mannitol Spermidine Retinol binding protein
b
Methylguanidine Spermine Tumor necrosis factor-α
b
Myoinositol
N
2,N
2-Dimethylguanosine
N
4-Acetylcytidine
N
6-Methyladenosine
N
6-Threonylcarbamoyladenosine
Orotic acid
Orotidine
Oxalate
Phenylacetylglutamine
Pseudouridine
SDMA
Sorbitol
Taurocyamine
Threitol
Thymine
Uracil
Urea
Uric acid
Uridine
Xanthine
Xanthosine
Not listed in the 2003 review by EUTox [5]
8-OH-2′Deoxyguanosine Phenylacetic acid Adiponectin
Dimethylguanosine Basic fibroblast growth factor
Guanilin Calcitonin-gene related peptide
Inosine Desacylghrelin
N-Methyl-2-pyridone-5-carboxamide Dinucleoside polyphosphates
b
Nitrosodimethylamine Ghrelin
Nitrosomethylamine Hepcidin
Phenylethylamine Interleukin-18
b
Thiocyanate Motiline
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trated on cardio-vascular damage with its known major
impact on morbidity and mortality [3, 4].
Focusing on the four main cell systems involved in
vascular damage necessitates consideration of the leuko-
cytes (monocytes and granulocytes), smooth muscle cells,
endothelial cells and thrombocytes. In 2001, the EUTox
group summarized the current expertise (Table 4)[ 2]. With
the sole exception of oxalate, all molecules involved in
vascular damage were either protein-bound and/or middle
molecules, i.e. compounds difficult to remove by standard
dialysis strategies. New knowledge collected since 2001
(Table 4) has not changed this perception. It should be
noted that one group of compounds included in Table 4, the
guanidines, are small and water-soluble, but recent data
indicate that their kinetic behavior is nevertheless markedly
different from that of our current marker compound, urea
[8, 9].
The most recently collected information is summarized
in the following sections.
Table 3 (continued)
Small water-soluble compounds Protein-bound compounds Middle molecules
Trimethylamine Octopamine
Orexin A
Substance P
Up4A
b
Uroguanylin
Vasoactive intestinal peptide
CMPF Carboxy-methyl-propyl-furanpropionic acid; ADMA Asymmetric dimethylarginine; DIP I Degranulation-inhibiting protein I; SDMA
Symmetric dimethylarginine; Up4A Uridine adenosine tetraphosphate
ap-Cresol, subsequently proven not to be present as such, but as conjugates, such as p-cresylsulfate
bMiddle molecules that are protein-bound at the same time
Table 4 Uremic toxins with a potential vascular impact
Uremic toxins Leukocytes Endothelial cells Smooth muscle cells Thrombocytes
Listed in the 2001 review by EUTox [2]
AGE
a x
c xx
AOPP
a xx
AGE-β2-microglobulin x
Angiogenin-DIP I x
β2-microglobulin x x x
Complement factor D x
Cytokines
a xx x x
Homocysteine
a xx x
Ig-light chain x
Leptin
a xx x
Oxalic acid
b x
Identified subsequent to the 2001 review by EUTox [2]
α-Fibrinogen fragments x
AII x
Guanidines
b x
Indoxyl sulfate x
NpxN
a xx
pCS x
Phenylacetic acid x
AGE advanced glycation end products; AOPP advanced oxidation protein products; NpxN dinucleotide polyphosphates; AII structural variants of
angiotensin II; pCS p-cresylsulfate
aCompounds that are protein-bound
bCompounds that are small and water-soluble
cThe "x" indicates that a biological effect was described that interferes with the corresponding cell system and which has the potential to induce in
this way vascular damage
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Dinucleoside polyphosphates are a group of substances
involved in the regulation of vascular tone as well as in the
proliferation of vascular smooth muscle cells [10] and
mesangial cells [11]. Specific members of this group, the
diadenosine polyphosphates, have been detected in hepato-
cytes, human plasma and platelets. In addition, increased
levels of diadenosine polyphosphates are present in
platelets from hemodialysis patients [12]. Uridine adeno-
sine tetraphosphate (Up4A) has recently been isolated and
identified as a novel endothelium-derived vasoconstrictive
factor. Its vasoconstrictive effects, plasma concentration
and release upon endothelial stimulation strongly suggest a
functional vasoregulatory role [13].
Structural variants of angiotensin II
Next to genuine angiotensin, structural variants, such as
angiotensin A, which is characterized by the decarbon-
ization of the asparagine molecule in the peptide, have been
described [14]. These structural variants also have vaso-
constrictive properties, be it less prominent than those of
genuine angiotensin II. The concentration of these variants
is increased in patients with CKD compared to subjects
with normal kidney function. It is conceivable that other
variants of angiotensin exist, are retained in patients with
kidney disease and play a pathophysiological role in
vascular dysfunction.
Advanced glycation end products (AGEs) and advanced
oxidation protein products (AOPPs)
Advanced glycation end products and AOPPs are generated
by oxidative processes and often incorporated into larger
molecules and peptide/protein structures. These, in turn,
activate inflammatory processes [15]. Although most of the
information obtained from earlier studies was generated by
artificially generated AGEs, more recent studies have
revealed that also AGE structures present in the body of
uremic patients have immune stimulating properties [16].
Recent data suggest that the classical methods for measur-
ing the concentration of AOPPs [17] are biased by an
unpredictable background noise created to a large extent by
triglycerides and coagulation factors [18, 19].
Interleukin-18 (IL-18)
Plasma IL-18, a pro-inflammatory cytokine, is increased in
patients with CKD, while its concentration is further raised
by hemodialysis with bioincompatible membranes [20].
The level of IL-18 is a strong predictor of poor outcome in
hemodialysis patients [21].
p-Cresylsulfate
Although most of the pioneering research on the phenolic
compounds has focused on the concentration and toxicity
of the mother compound p-cresol, later work revealed that
genuine p-cresol is present only at very low concentrations
in patients with renal failure and that most of the p-cresol
generated by the intestinal flora conjugates to p-cresylsul-
fate in the intestinal wall and to p-cresylglucuronide in the
liver [22, 23]. Both conjugates are characterized by a strong
protein binding. The primary reason for the earlier—
incorrect—emphasis on p-cresol is that most of the earlier
determination methods were based on deproteinization by
acidification, which causes the disintegration of the
conjugates by hydrolysis. Application of deproteinization
methods without the acidification step revealed the pres-
ence of the conjugate p-cresylsulfate [22]. Further studies
indicated that the biochemical impact of the mother
compound p-cresol is not necessarily the same as that of
the conjugate. Whereas p-cresol suppresses the activity of
leukocytes, especially after their activation, p-cresylsulfate
essentially appears to be linked to baseline leukocyte
activation [24]. Nevertheless, since there is very likely a
correlation between former p-cresol estimations and current
p-cresylsulfate measurements, previously held conclusions
about protein binding and the relationship of p-cresylsul-
fate with clinical outcome parameters of p-cresol [25–27]
are likely still valid.
Indoles
The indoles are another group of protein-bound compounds
that are generated by chemical transformation processes,
such as conjugation. Indoxyl sulfate, the most abundant
indolic compound in the body of uremic patients, has been
linked to endothelial damage, inhibition of endothelial
regeneration and repair, and endothelial free radical
production [28, 29]. Indoxyl sulfate has also been related
to renal fibrosis and the progression to renal failure [30,
31]. The absorbent AST-120 (Kremezin) decreases serum
and urine concentration of indoxyl sulfate in rats [32]. A
large prospective clinical study in humans with AST-120
demonstrated a decrease in the plasma concentration of
indoxyl sulfate, but showed no clinical benefit [33],
possibly because the running time of the study was too
short.
Guanidines
The guanidines are, relative to urea, small water-soluble
protein breakdown products. They have long been consid-
ered to be neurotoxins [34], but more recently, they have
also been linked to vascular damage based on a study
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activated leukocyte function [35]. In addition, guanidines
have also been shown to modify albumin structure in such a
way as to decrease the protein binding of homocysteine
(HCy) [36], hence stimulating the release of free, active
HCy and enhancing the cardio-vascular damaging potential
of this compound.
The concentration of another guanidine, asymmetrical
dimethyl arginine (ADMA), has been related to several
parameters of vascular outcome [37, 38]. Symmetrical
dimethyl arginine (SDMA), a structural variant of ADMA,
had been considered inert until recently, but it has now been
suggested to be related to vascular damage through its
inhibition of inducible nitric oxide synthase (iNOS) [39].
Although the guanidines are small and water soluble,
they nevertheless show a kinetic behavior that diverges
from that of urea, as demonstrated by calculated kinetic
analyses [8] and confirmed recently by direct measurements
[9]. The distribution volume of most guanidines appears to
be much larger than that of urea, hence resulting in more
difficult removal and increased rebound at the end of
dialysis [8].
Therapeutic implications
Diffusive-convective removal through large pore
membranes
Since many of the molecules involved in the biochemical/
biological side-effects of chronic kidney failure have a
relatively high MW, it might be useful to combat those
complications by removing those molecules, i.e. dialyzing
through membranes with a larger pore size (so-called high-
flux membranes). Several studies have convincingly dem-
onstrated that the use of such membranes has the extra
bonus of removing several important middle molecules
with patho-physiological potential. In contrast, standard
dialysis barely removes these compounds or does not
remove them at all [40–42]. In fact, the concentrations of
these compounds actually tend to increase during standard
dialysis due to hemoconcentration as a consequence of the
extraction of the extra fluid that has accumulated in the
body in between dialysis sessions in combination with no
effective removal.
At the end of the previous century, the results of
several observational studies suggested that dialysis
through large pore (high-flux) membranes resulted in a
survival advantage versus dialysis through standard
small-pore (low-flux) membranes [41, 43–45]. Controlled
prospective studies, however, were not undertaken in this
area until 2002, when the HEMO-study was published [46].
The HEMO-study is a randomized trial, undertaken in
predominantly American (USA) hemodialysis patients, that
comprises four different arms, one comparing standard with
high-dose dialysis adequacy, as defined by Kt/Vurea, and the
other comparing low-flux with high-flux membranes. The
study protocol adhered to a rather “conservative” definition
of high flux with relatively low minimum ultrafiltration
coefficients, allowed dialyzer reuse and short dialysis times
and was based on a follow-up of 1–5 years. Although this
study was unable to demonstrate the superiority of high-
flux at the primary analysis with overall mortality as an
end-point [46], the secondary analysis revealed that the
high-flux membranes had an advantage in terms of cardio-
vascular morbidity and mortality [47], cerebrovascular
morbidity/mortality [48] and overall mortality in those
patients who enrolled in the study after having undergone
dialysis prior to enrollment for a longer period than the
median time on dialysis of the global group, which was
3.7 years [47]. Another subanalysis showed a relationship
between the concentration of the middle molecule β2-
microglobulin and outcome, irrespective of the type of
membrane [49].
Subsequent to the HEMO-study, two studies in dialyzed
populations developed with other primary endpoints than
the comparison of membrane porosity (one study focusing
on nutritional aspects, another on the impact of statins on
outcome) demonstrated at secondary analysis a survival
advantage for high-flux versus low-flux membranes [50, 51].
The Membrane Permeability Outcome (MPO)-study is a
two-armed European controlled study comparing only high-
flux and low-flux membranes and essentially recruiting
among dialysis patients with a deteriorated clinical condi-
tion by focusing on hypoalbuminemic patients [52]. In
comparison with the HEMO-study, high-flux was defined
more strictly, and dialysis times were longer, reuse was not
allowed and follow-up stretched over 3–7.5 years. Among
the hypoalbuminemic patients and also in the subgroup
affected by diabetes mellitus, a survival advantage was
found for patients treated with high-flux membranes
(presentation by F. Locatelli at the ERA–EDTA meeting
in Barcelona, June 2007).
In summary, many data support the concept that an
enhancement of the removal of middle molecules by
applying large-pore high-flux membranes creates a survival
advantage, especially among dialysis patients with a bleak
prognosis, such as the diabetics, the malnourished, the
inflamed and those with atheromatosis or at least at risk for
atheromatous disease.
Based on information collected before the publication
of the MPO-study, the second wave of European Best
Practice Guidelines (EBPG) for hemodialysis recommen-
ded the use of high-flux membranes [53]. The controlled
data collected in the MPO-study has only strengthened
this recommendation.
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If increasing the pore size of the dialyzer creates a survival
advantage, adding to the removal of larger molecules by
increasing convection may be an additional asset. Several
studies have demonstrated that convective strategies en-
hance dialytic removal of the middle molecules [54–56].
Optimization of this process was previously hampered by
the need to substitute ultrafiltered volume by sterile
pharmacologically prepared solutions, but the creation of
the possibility to generate ultrapure dialysate for substitu-
tion purposes has enabled the exchanged volumes to be
increased and removal to be maximized.
Data evaluating the outcomes of these convective
strategies are relatively scarce. In one prospective study,
the prevalence of carpal tunnel syndrome, as a reflection
of dialysis-related amyloidosis, was decreased by convec-
tive strategies [57]. In the same study, mortality decreased
by 10% in the patient group on convection, but this
difference was statistically not significant. A prospective
comparison of patients on pre-dilution on-line hemofiltra-
tion with standard low-flux hemodialysis showed a better
quality of life and nutritional status with hemofiltration
[58]. In an observational analysis of the DOPPS database,
on-line hemodiafiltration with high substitution volumes
w a sl i n k e dt oas u r v i v a la d v a n t a g e[ 59]. Also, a smaller
observational study from the USA showed a striking
survival advantage [60]. A Dutch study comparing high-
flux hemodiafiltratrion with high-flux dialysis has been
started, but the enrolment phase has as yet not been
finalized [61].
In conclusion, the suggestion was made as early as
2001, that many of the compounds with the potential to
damage the cardio-vascular system have a kinetic behavior
that differs from that of urea, the currently universally
applied marker of uremic retention and dialysis adequacy
[2]. More recent data confirm this position statement:
cardio-vascular toxins are quite often uremic retention
compounds which are so-called “difficult to remove by
dialysis”, either middle molecules, protein-bound mole-
cules or molecules like the guanidines, with a kinetic
behavior that differs markedly from that of urea. Given this
information, the nephrological community should be aware
of the fact that in terms of uremic toxicity, there are more
factors at play than urea alone and that when faced with
removing uremic toxins, the nephrologist should aim at
removing more than only urea.
Protein-bound molecules
At least three studies suggest a correlation between the
concentration of protein-bound uremic retention solutes and
clinical outcome parameters [25–27]. However, to date,
there are no interventional studies on the effect of
improving the removal of protein-bound molecules in
uremia on outcome, simply because most of the current
removal strategies are not superior to standard hemodialysis
in their removal capacity of protein-bound molecules.
High-flux hemodialysis has no impact on the concentration
of protein-bound uremic retention solutes when compared
to low-flux hemodialysis [7]. It is likely that more complex
strategies, such as extreme convective therapies or adsorp-
tion, will be necessary to induce the removal of any
significance.
Pharmacological interventions
Further study is needed to characterize the as yet uniden-
tified uremic retention solutes and to fine-tune our
knowledge of the molecular role of known and newly
identified compounds. Instead of concentrating on com-
pounds with a known effect, it may be more rewarding to
apply unbiased techniques in the proteomic, genomic and
metabonomic fields using refined biostatistic tools to link
mediators to clinical outcome. This would appear to be the
only approach to identify new elements and mechanisms,
which in their turn, in a second stage, may be relevant for
the general population as well.
There is also a need for a classification system based on
importance of the identified culprits.
In addition to more specific removal methods than the
ones applied today, a search for pharmaceutical strategies
blocking the molecular impact of uremic solutes is one of
the next steps. Such strategies would be based on identified
patho-physiological mechanisms and would allow the
prevention and treatment in the less severely affected
CKD groups long before the need for extracorporeal renal
replacement. The final aim here should be to prevent
cardio-vascular and other complications and the evolution
towards renal replacement therapy.
Variability in reported concentrations
An often overlooked cause of bias in the interpretation of
uremic toxicity is the marked variability in the reported
concentrations of uremic retention solutes [62, 63]. Al-
though such a variability has been observed for many
solutes, it seems to be a problem that is more frequently
associated to the protein-bound molecules, middle mole-
cules and guandines (Table 5). This variability may be at
the origin of several potential errors (Table 6), such as the
choice of unreliable concentrations of uremic solutes for in
vitro experiments, but it may also cause erroneous
therapeutic decisions or incorrect interpretation of pre-
sumed biological/toxic effects (Table 6).
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Data on uremic toxin concentration in children are very
scanty, and even an intensive literature search results in the
finding of extremely scarce data. In one study, the
distribution of urea concentrations in relation to kidney
function for Italian children was reported [64], there was no
consideration of the potential patho-physiological conse-
quences. A better knowledge of the behavior of uremic
toxins in children is desirable in view of their differences in
metabolism and distribution volume versus those of adults.
Hence, it is not acceptable to automatically extrapolate data
from the adult population to children.
Conclusions
In view of dialysis remaining the main therapeutic strategyto
counteract the clinical impact of uremic retention molecules,
especially at a later stage of CKD, the most practical
approach still appears to be that of adhering to a subdivision
of uremic solutes into: (1) small water-soluble compounds;
(2) middle molecules; (3) protein-bound solutes.
Uremic toxin retention is a complex condition, implying
a large number of retention products and far more
compounds than only the small water-soluble solutes.
Hence, we should be aware of this when interpreting the
value of urea or creatinine as markers of uremic retention
and realize that there are more players in uremia than urea
and creatinine alone. Likewise, removal strategies should
be aimed at the removal of more than urea alone, especially
since the larger middle molecules and the protein-bound
uremic compounds seem to be related to deleterious
biological, biochemical and clinical effects. New moieties
with a potential impact, especially in the context of cardio-
vascular morbidity and mortality, which remain among the
main clinical problems in kidney failure, are detected
continually and should lead to new therapeutic approaches.
The number of larger and/or protein-bound molecules
among these compounds also is substantial.
The removal of larger “middle” molecules is likely to be
related to better outcomes, as previously suggested by the
results of observational studies and recently confirmed in
sub-analyses and primary analyses of well-designed con-
trolled studies.
The concentration of protein-bound uremic solutes is
also related to clinical outcome but, until recently, no
strategies had been characterized that enhance their removal
convincingly. With the development of such strategies, it
may be expected that it will become possible to design
controlled interventional studies evaluating the effect of
removing these protein-bound molecules.
Variability in reported concentrations may result in the
incorrect interpretation of presumed toxic effects and/or in
clinical mistakes.
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